← All trials
NCT01410214
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2011
- Primary completion
- Jul 1, 2015
- Completion date
- Jul 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Chinese Lung Cancer Surgical GroupLead sponsor
- Tianjin Medical UniversityOverall official - principal investigator
- Fudan UniversityCollaborator
- Qingdao UniversityCollaborator
- Harbin Medical UniversityCollaborator
- The Second People's Hospital of SichuanCollaborator
- Sun Yat-Sen UniversityCollaborator
- Zhejiang UniversityCollaborator
- Soochow UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Peking UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Hebei UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.